JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2021, 70(5):179-185 | DOI: 10.5817/CSF2021-5-179

The effect of meloxicam and cryopreserved placenta extract on initial inflammatory response - an experimental study

Fedir V. Hladkykh1,2
1 Department of Experimental Cryomedicine, Institute for Problems of Cryobiology and Cryomedicine of the National Academy of Sciences of Ukraine, Kharkiv, Ukraine
2 Junior Research fellow of the Radiation Therapy Group at the Radiology Department, State Organization «Grigoriev Institute for medical Radiology and Oncology National Academy of Medical Sciences of Ukraine»

Alteration is the first phase of the inflammatory process triggering the entire cascade of inflammation and causing destructive changes in the affected tissues. Therefore, suppression of inflammation at this point is essential for the success of anti-inflammatory therapy. Previous experimental studies have shown that the combined use of nonsteroidal anti-inflammatory drugs and drugs with pleiotropic mechanisms of action may potentiate their anti-inflammatory properties. The purpose of my work was to characterize the combined effect of cryopreserved placenta extract and meloxicam on the alterative phase of the inflammatory process in a model of aseptic skin and subcutaneous tissue inflammation in rats. Subcutaneous administration of acetic acid and of dextran was found to result in formation of necrotic ulcers in 100% of rats by day 7 of the experiment. The most pronounced antialterative effect (23.9%) on day 7 of the experiment was observed with the combined use of meloxicam and cryopreserved placenta extract - the area of necrotic ulcers was 1.3-fold smaller (p < 0.05) as compared with control rats (without treatment). On day 27 of the experiment, the antialterative effect of combined treatment and prophylactic use of meloxicam and cryopreserved placenta extract was 1.7 times higher than the effect in meloxicam monotherapy group, and 1.2 times higher than that in the placenta cryoextract monotherapy group.

Keywords: inflammation; cryopreserved placenta extract; meloxicam; alteration

Received: July 2, 2021; Accepted: September 21, 2021; Published: May 1, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hladkykh FV. The effect of meloxicam and cryopreserved placenta extract on initial inflammatory response - an experimental study. Čes. slov. farm. 2021;70(5):179-185. doi: 10.5817/CSF2021-5-179.
Download citation

References

  1. Drogovoz S., Marchyshyn S., Shchokina K., Kozyr H., Baev O. Experimental study of pharmacological activity of garden nasturtion on necrotic ulcers model in rats. Farm. Zh. 2011; 5, 92-95. Available from: https://pharmj.org.ua/index.php/journal/article/view/596
  2. Hladkykh F., Chyzh M. Modulation of meloxicam-induced changes in gastrointestinal and motor activity of the stomach by applying placenta cryoextract. Proc. Shevchenko Sci. Soc. Med. Sci. 2021; 64 (1), 84-94. doi: https://doi.org/10.25040/10.25040/ntsh2021.01.08. Available from: https://mspsss.org.ua/index.php/journal/article/view/400 Go to original source...
  3. Hladkykh F. V. Preventive-therapeutic strategies of pharmacocorrection of gastropathy induced by non-steroidal anti-inflammatory drugs. Reviews of clin. Pharm. and drug ther. 2017; 4, 14-23. doi: http://dx.doi.org/10.17816/RCF15414-23 Go to original source...
  4. Goltsev A. N. (ed.) Placenta: cryopreservation, clinical use. Kharkiv: Brovin 2013.
  5. Hladkykh F. V., Chyzh M. O. Nonsteroidal anti-inflammatory drugs: a modern understanding of the mechanisms of damage to the digestive tract, the shortcomings of pathogenetic drugs and prospects for biological therapy of NSAID-induced esophagogastroenterocolonopathy. Gastroenterology 2020, 54 (4), 253-66. doi: https://doi.org/10.22141/2308-2097.54.4.2020.216714 Go to original source...
  6. Pogozhykh O., Prokopyuk V., Figueiredo C., Pogozhykh D. Placenta and placental derivatives in regenerative therapies: experimental studies, history, and prospects. Stem Cells Int. 2018; 2018, 1-14. doi: https://doi.org/10.1155/2018/4837930 Go to original source... Go to PubMed...
  7. Ren L., Meng L., Yan H., Sun W., Yao D. Preoperative meloxicam versus postoperative meloxicam for pain control, patients' satisfaction and function recovery in hip osteoarthritis patients who receive total hip arthroplasty: a randomized, controlled study. Inflammopharmacol. 2020; 28(4), 831-838. doi: https://doi.org/10.1007/s10787-020-00718-2 Go to original source... Go to PubMed...
  8. Vogel H. G. (ed.) Drug Discovery and Evaluation: Pharmacological Assays Berlin, Heidelberg: Springer 2008.
  9. Menkin V. N. Biochemical mechanisms in inflammatation. Sprigfield: Thomas 1956.
  10. Butko Y., Tkachova O., Tishakova T., Gordienko A., Bondariev Y. Wound healing effect of "Prolidoxid" and "Dexpanthenol withceramides": a сomparative study based on the model of chemical burns with expressed alterative skin processes. SR: Pharm. Sci. 2021; 2(30), 26-32. doi: http://doi.org/10.15587/2519-4852.2021.230031 Go to original source...
  11. Bondarenko P. S., Voloshchuk N. І. Investigation of anti-inflammatory and antipyretic activity of polymorphic modification of n-(trifluoromethylphenyl)-4-hydroxy- 2,2-dioxo-1h-2λ6,1-benzothiazine-3-carboxamide derivative in rats. Reports of VNMU 2021; 25(1), 27-31. doi: https://doi.org/10.31393/reports-vnmedical-2021-25(1)-05 Go to original source...
  12. Hladkykh F. V., Chyzh M. O., Manchenko A. O., Belochkina I. V., Mikhailova I. P. Effect of cryopreserved placenta extract on some biochemical indices of therapeutic efficiency and toxicity of diclofenac sodium in adjuvant-induced experimental arthritis. Pharmacy & Pharmacology 2021; 9(4), 278-293. doi: https://doi.org/10.19163/2307-9266-2021-9-4-278-293 Go to original source...




Czech and Slovak Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.